Dendreon (DNDN) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 06, 2013
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'DENDREON CORP	'
Entity Central Index Key	'0001107332	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	157,487,323

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$87,694	$188,408
Short-term investments	78,947	165,396
Trade accounts receivable	34,711	38,884
Inventory	96,116	76,300
Prepaid expenses and other current assets	20,308	18,302
Total current assets	317,776	487,290
Property and equipment, net	132,130	150,604
Long-term investments	66,708	76,045
Other assets	5,526	7,180
Total assets	522,140	721,119
Current liabilities:	'	'
Accounts payable	7,881	12,845
Accrued liabilities	46,489	44,821
Accrued compensation	20,828	27,050
Restructuring and contract termination liabilities	4,843	14,214
Current portion of convertible debt	27,685	'
Current portion of capital lease obligations	2,400	4,418
Current portion of facility lease obligations	629	594
Total current liabilities	110,755	103,942
Long-term accrued liabilities	5,676	5,081
Capital lease obligations, less current portion	4,244	6,219
Facility lease obligations, less current portion	10,296	10,835
Convertible senior subordinated notes due 2014	'	27,685
Convertible senior notes due 2016, net of discount	552,326	532,744
Commitments and contingencies (Note 13)	'	'
Stockholders' equity (deficit):	'	'
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding	'	'
Common stock, $0.001 par value; 250,000,000 shares authorized, 157,644,031 and 154,414,811 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	152	150
Additional paid-in capital	2,001,028	1,988,666
Accumulated other comprehensive income	75	147
Accumulated deficit	-2,162,412	-1,954,350
Total stockholders' equity (deficit)	-161,157	34,613
Total liabilities and stockholders' equity (deficit)	$522,140	$721,119

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Stockholders' equity (deficit):	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	157,644,031	154,414,811
Common stock, shares outstanding	157,644,031	154,414,811

Consolidated_Statements_Of_Ope

Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements Of Operations [Abstract]	'	'	'	'
Product revenue, net	$67,982	$77,942	$208,848	$239,878
Royalty and other revenue	20	29	63	159
Total revenue	68,002	77,971	208,911	240,037
Operating expenses:	'	'	'	'
Cost of product revenue	46,933	51,749	134,106	173,521
Research and development	17,579	18,643	54,190	55,683
Selling, general and administrative	56,207	68,109	185,484	243,643
Restructuring, contract termination and asset impairment	1,188	80,994	2,844	81,969
Total operating expenses	121,907	219,495	376,624	554,816
Loss from operations	-53,905	-141,524	-167,713	-314,779
Other income (expense):	'	'	'	'
Interest income	158	313	553	1,071
Interest expense	-13,458	-13,732	-40,973	-41,312
Other income (expense)	-10	79	71	105
Net loss	($67,215)	($154,864)	($208,062)	($354,915)
Basic and diluted net loss per share	($0.44)	($1.04)	($1.37)	($2.39)
Shares used in computation of basic and diluted net loss per share	152,246	149,593	151,849	148,455

Consolidated_Statements_Of_Com

Consolidated Statements Of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Consolidated Statements Of Comprehensive Income (Loss) [Abstract]	'	'	'	'
Net loss	($67,215)	($154,864)	($208,062)	($354,915)
Other comprehensive income (loss):	'	'	'	'
Net unrealized gain (loss) on securities	90	119	-72	243
Comprehensive loss	($67,125)	($154,745)	($208,134)	($354,672)

Consolidated_Statements_Of_Cas

Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Operating Activities:	'	'
Net loss	($208,062)	($354,915)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation expense	23,829	31,152
Non-cash stock-based compensation expense	11,950	57,264
Amortization of securities discount and premium	2,044	2,292
Amortization of convertible notes discount and debt issuance costs	21,189	19,597
Asset impairment related to restructuring and contract termination	'	65,295
Other	519	306
Changes in operating assets and liabilities:	'	'
Trade accounts receivable	4,173	-2,766
Inventory	-17,720	9,382
Prepaid expenses and other assets	-4,096	-2,714
Accounts payable	-4,964	3,071
Accrued liabilities and compensation	-4,269	6,345
Restructuring and contract termination liabilities	-9,371	11,109
Net cash used in operating activities	-184,778	-154,582
Investing Activities:	'	'
Maturities and sales of investments	170,734	192,256
Purchases of investments	-77,268	-222,052
Purchases of property and equipment	-5,424	-14,490
Net cash provided by (used in) investing activities	88,042	-44,286
Financing Activities:	'	'
Payments on facility lease obligations	-504	-755
Payments on capital lease obligations	-3,993	-2,068
Proceeds from deposits	329	1,866
Payments of security deposits	'	-1,779
Issuance of common stock under the Employee Stock Purchase Plan	1,006	2,795
Net proceeds from the exercise of stock options	41	247
Other	-857	-1,842
Net cash used in financing activities	-3,978	-1,536
Net decrease in cash and cash equivalents	-100,714	-200,404
Cash and cash equivalents at beginning of period	188,408	427,100
Cash and cash equivalents at end of period	87,694	226,696
Supplemental Disclosure of Cash Flow Information:	'	'
Cash paid during the period for interest	24,416	17,981
Increase in asset retirement obligation	'	$745

Business_Principles_Of_Consoli

Business, Principles Of Consolidation, And Basis Of Presentation	9 Months Ended
	Sep. 30, 2013
Business, Principles Of Consolidation, And Basis Of Presentation [Abstract]	'
Business, Principles Of Consolidation, And Basis Of Presentation	'
	DENDREON CORPORATION
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
	(Unaudited)
	1. BUSINESS, PRINCIPLES OF CONSOLIDATION AND BASIS OF PRESENTATION
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration (“FDA”), and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
	Basis of Presentation
	The accompanying unaudited financial statements reflect, in the opinion of management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations and cash flows for each period presented in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from the accompanying statements. These interim financial statements should be read in conjunction with the audited financial statements and related notes thereto, included in our Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Form 10-K”). The accompanying financial information as of December 31, 2012 has been derived from the Company’s audited 2012 consolidated financial statements included in the 2012 Form 10-K. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of future results that may be expected for the year ending December 31, 2013, or any other future period.

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. For sales of our product to eligible Medicaid patients, the physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”), providing for a chargeback on sales to PHS-eligible providers, and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible patients. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable.
	The following is a roll forward of our chargebacks reserve associated with the PHS and FSS programs:
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		10,426		12,837
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,128		—
	Payments/credits		-8,399		-13,394
	Balance at September 30	$	3,006	$	6,558
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Beginning in July of 2012, eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. We recorded chargebacks related to the GPOs of $2.4 million and $5.2 million for the three and nine months ended September 30, 2013, respectively, and $0.1 million for each of the three and nine months ended September 30, 2012.
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales of our product to eligible GPO members. The following is a roll forward of our accrued GPO rebates and administrative fees balance:
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		4,682		5,719
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-5,054		-4,734
	Balance at September 30	$	1,578	$	1,927
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method. We began capitalizing raw material inventory in mid-April 2009, in anticipation of the potential approval for marketing of PROVENGE in the first half of 2010. At this time, our expectation of future benefits became sufficiently high to justify capitalization of these costs, as regulatory approval was considered probable and the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to mid-April 2009 were recorded as research and development expense in the statements of operations, which resulted in zero-cost inventory.
	For the nine months ended September 30, 2012, we used $4.7 million of zero-cost inventory; no zero-cost inventory remained on hand as of June 30, 2012. As a result, cost of product revenue reflects a lower average per unit cost of raw material in the first half of 2012.
	Restructuring and Contract Termination Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred. Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract. Refer to Note 12 – Restructuring and Contract Termination for details of restructuring expenses recorded in the third quarter of 2013 and Note 14 – Subsequent Events for additional actions that will be implemented in the fourth quarter of 2013.
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
	The long-lived assets at our manufacturing facilities in Atlanta, Georgia and in Orange County, California represent our most significant long-lived assets and have an average remaining estimated useful life of approximately 7.5 years.  Our determination of the cash flows used to support the recoverability of these assets requires us to estimate future revenue growth and costs of operations, requiring significant management judgments. The estimates we used to forecast the future operating results are consistent with the plans and estimates that we use to manage our business. Significant assumptions utilized in this analysis as of September 30, 2013 included maintaining our current revenue levels and successfully implementing the cost reduction measures as further discussed in Note 14 – Subsequent Events. The recoverability test is particularly sensitive to our estimates of future revenue and operating expenses. For example, in our recoverability analysis as of September 30, 2013, a decrease in our revenue assumptions for future periods of less than 2%, without a corresponding decrease in operating expenses, would have indicated that the undiscounted cash flows were insufficient to recover the carrying value of our facility assets. In this analysis, the undiscounted cash flows exceeded the current net book value of our facility assets by 10%. Although we believe that our current underlying assumptions supporting this assessment are reasonable, if actual product revenues do not meet the levels we have forecasted or if we do not achieve the reductions in operating expense we have forecasted, we may be required to update the assumptions in our impairment analysis. Such updates to this analysis may impact the recoverability of these assets, which may result in a material charge to our statement of operations.
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options is calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards. We determine the fair value of awards under our Employee Stock Purchase Plan using the BSM model.
	Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
	Stock-based compensation expense also requires the estimate of forfeiture rates. In the first and second quarters of 2013, we adjusted our estimated forfeiture rates based on historical forfeiture data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $5.8 million for the nine months ended September 30, 2013. These adjustments decreased basic and diluted net loss per share by $0.04 for the nine months ended September 30, 2013.
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. For the calculation of diluted net loss per share, we have excluded all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) from the calculation because all such securities are anti-dilutive, and accordingly, our diluted net loss per shares is the same as basic net loss per share. For the three and nine months ended September 30, 2013 and 2012, the computation of diluted net loss per share excluded 22.9 million shares and 23.1 million shares, respectively.
	Comprehensive Income (Loss)
	Comprehensive income (loss) includes charges and credits to stockholders’ equity that are not the result of transactions with stockholders. Our comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the three and nine months ended September 30, 2013 and 2012.
	Loss Contingencies
	A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to make a reasonable estimate of the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued an Accounting Standards Update which requires companies to provide information about the amounts reclassified from accumulated other comprehensive income to net income by component. In addition, companies are required to present, either on the face of the statements of operations or in the notes to the financial statements, significant amounts reclassified from accumulated other comprehensive income by statement of operations line item. There were no reclassifications from accumulated other comprehensive income to net income for the three and nine months ended September 30, 2013.
	In June 2013, the FASB ratified Emerging Issues Task Force (“EITF”) Issue 13-C, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” which concludes that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when settlement in this manner is available under the tax law. We will adopt this amendment as of January 2014, and do not believe it will have any impact on our financial position, results of operations or cash flows.
	For a more detailed listing of our significant accounting policies, see Note 2 of the consolidated financial statements included in the 2012 Form 10-K.

Investments

Investments	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
Investments	'
	3. INVESTMENTS
	Securities available-for-sale at cost or amortized cost and fair market value by contractual maturity were as follows:
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	September 30, 2013
	Due in one year or less	$	78,893	$	78,947
	Due after one year through two years		66,687		66,708
		$	145,580	$	145,655
	December 31, 2012
	Due in one year or less	$	165,295	$	165,396
	Due after one year through two years		75,999		76,045
		$	241,294	$	241,441
	Our gross realized gains and losses on sales of available-for-sale securities were not material for the three and nine months ended September 30, 2013 and 2012.
	Securities available-for-sale, short-term and long-term, consisted of the following:
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	September 30, 2013
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		94,535		46		-24		94,557
	Government-sponsored enterprises		13,147		20		—		13,167
	U.S. Treasury notes		32,494		33		—		32,527
		$	145,580	$	99	$	-24	$	145,655
	December 31, 2012
	Demand deposit	$	5,641	$	—	$	—	$	5,641
	Corporate debt securities		104,652		91		-17		104,726
	Government-sponsored enterprises		33,438		18		—		33,456
	U.S. Treasury notes		97,563		57		-2		97,618
		$	241,294	$	166	$	-19	$	241,441
	None of the securities have been in a continuous unrealized loss position for more than 12 months as of September 30, 2013.
	Market values were determined for each individual security in the investment portfolio. We utilize third-party pricing services for all security valuations. We review the pricing methodology, including the collection of market information, used by the third-party pricing services. On a periodic basis, we also review and validate the pricing information received from the third-party providers.
	The declines in value of these investments are primarily related to changes in interest rates and are considered to be temporary in nature. We evaluate, among other things, the duration and extent to which the fair value of a security is less than its cost, the financial condition of the issuer, and our intent to sell, or whether it is more likely than not that we will be required to sell the security before recovery of the amortized cost basis. We have the ability and intent to hold these securities to maturity; therefore we do not consider these investments to be other-than-temporarily impaired as of September 30, 2013. Refer to Note 4 – Fair Value Measurements for further discussion.
	Investments securing letters of credit in the aggregate amount of $5.4 million as of September 30, 2013 and $5.6 million as of December 31, 2012 are classified as long-term investments.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	4. FAIR VALUE MEASUREMENTS
	We measure and report at fair value cash equivalents and investment securities (financial assets). Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The hierarchy of fair value measurements is described below:
	Level 1 —  Observable inputs for identical assets or liabilities such as quoted prices in active markets;
	Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs); and
	Level 3 — Unobservable inputs in which little or no market data exists, therefore determined using estimates and assumptions developed by us, which reflect those that a market participant would use.
	The following summarizes financial assets measured at fair value on a recurring basis:
	3 an
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	September 30, 2013
	Money market	$	83,289	$	83,289	$	—
	Corporate debt securities		94,557		—		94,557
	Government-sponsored enterprises		13,167		—		13,167
	U.S. Treasury notes		32,527		—		32,527
	Total financial assets		223,540	$	83,289	$	140,251
	Add: Cash		9,809
	Total cash, cash equivalents and investments	$	233,349
	December 31, 2012
	Money market	$	184,167	$	184,167	$	—
	Corporate debt securities		104,726		—		104,726
	Government-sponsored enterprises		33,456		—		33,456
	U.S. Treasury notes		97,618		—		97,618
	Total financial assets		419,967	$	184,167	$	235,800
	Add: Cash		9,882
	Total cash, cash equivalents and investments	$	429,849
	Fixed income investment securities are valued using the market approach. We had no Level 3 financial assets for either period presented.
	The fair value of the 2016 Notes as of September 30, 2013 and December 31, 2012 was approximately $378.6 million and $471.2 million, respectively, based on the last trading prices as of the respective period end. The fair value of the 2014 Notes as of September 30, 2013 was approximately $26.3 million based on average trading prices near period end. The fair value of the 2014 Notes as of December 31, 2012 was approximately $25.3 million based on the last trading price as of the period end. Estimates of fair value for the 2016 Notes and the 2014 Notes are based on Level 2 inputs.
	The carrying amounts reflected in the consolidated balance sheets for cash, prepaid expenses, other current assets, accounts payable, accrued expenses and other liabilities approximate fair value due to their short-term nature. In addition, our capital lease obligations approximate fair value based on current interest rates, which contain an element of default risk.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory [Abstract]	'
Inventory	'
	5. INVENTORY
	Inventories, stated at the lower of cost or market, consisted of raw materials of $96.1 million as of September 30, 2013 and $76.3 million as of December 31, 2012.
	In the third quarter of 2013, we recorded a charge of $6.3 million related to antigen inventory which was determined to fall out of quality specification and was not usable for commercial production. This charge is included in “Cost of product revenue” on our consolidated statement of operations for the three and nine months ended September 30, 2013. We have filed an insurance claim to seek recovery of the $6.3 million loss; however, at this time we are uncertain if this loss will be reimbursed by our insurance carriers.
	We have also identified an additional $38.0  million of antigen inventory at risk of being out of quality specification. We have initiated an investigation to determine the usability of this remaining antigen inventory. If we determine that this inventory is not usable for commercial production, we will seek reimbursement for the loss from our insurance carriers; however, at this time we are uncertain if the loss, if any, will be reimbursed by our insurance carriers.

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	9 Months Ended
	Sep. 30, 2013
Prepaid Expenses And Other Current Assets [Abstract]	'
Prepaid Expenses And Other Current Assets	'
	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS
	We utilize a third-party supplier, Fujifilm Diosynth Biotechnologies (“Fujifilm”), to manufacture the recombinant antigen used in the manufacture of PROVENGE. As of September 30, 2013 and December 31, 2012, there was $0.5 million and $0.6 million, respectively, included in “Prepaid expenses and other current assets” on the consolidated balance sheets related to costs associated with the purchase of the antigen.
	As of September 30, 2013 and December 31, 2012, there was $6.9 million and $8.5 million, respectively, included in “Prepaid expenses and other current assets” on the consolidated balance sheets related to costs associated with agreements to develop second source suppliers for materials used in the manufacture of PROVENGE, and to qualify a contract manufacturer for production.

Property_And_Equipment

Property And Equipment	9 Months Ended
	Sep. 30, 2013
Property And Equipment [Abstract]	'
Property And Equipment	'
	7. PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following:
		September 30,		December 31,
		2013		2012
		(In thousands)
	Furniture and office equipment	$	2,792	$	2,111
	Laboratory and manufacturing equipment		29,903		29,590
	Computer equipment and software		69,158		66,117
	Leasehold improvements		117,242		115,735
	Buildings		17,872		17,872
	Construction in progress		2,112		2,313
		$	239,079	$	233,738
	Less accumulated depreciation		-106,949		-83,134
		$	132,130	$	150,604
	The buildings under our manufacturing facility leases must be restored to original condition upon lease termination. Accordingly, we have accrued the estimated costs of dismantlement and restoration associated with these obligations. The asset retirement obligations related to manufacturing facilities in Atlanta, Georgia (the “Atlanta Facility”) and in Orange County, California (the “Orange County Facility”) are included in “Long-term accrued liabilities” on the consolidated balance sheets.
	For further description of the facility leases refer to Note 9 – Financing Obligations and Note 13 – Commitments and Contingencies.
	Depreciation expense, including depreciation of assets acquired through capital leases, for the three and nine months ended September 30, 2013 was $8.1 million and $23.8 million, respectively, and for the three and nine months ended September 30, 2012 was $9.5 million and $31.2 million, respectively.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Accrued Liabilities	'
	8. ACCRUED LIABILITIES
	Accrued liabilities consisted of the following:
		September 30,		December 31,
		2013		2012
		(In thousands)
	Deferred rent	$	7,193	$	7,875
	Inventory receipts		15,672		6,636
	Accrued consulting and other services		7,249		12,016
	Accrued clinical trials expense		2,909		2,299
	Accrued interest		4,097		8,234
	Accrued service fees and rebates		2,467		3,533
	Other accrued liabilities		6,902		4,228
		$	46,489	$	44,821

Financing_Obligations

Financing Obligations	9 Months Ended
	Sep. 30, 2013
Financing Obligations [Abstract]	'
Financing Obligations	'
	9. FINANCING OBLIGATIONS
	We lease the Orange County Facility and the Atlanta Facility, but were deemed owner of each of these manufacturing facilities during their construction periods under build-to-suit lease accounting. Upon completion of the facilities, we continued to be deemed owner, and were required to capitalize building costs related to each facility. We therefore capitalized building costs of $6.7 million related to the Orange County Facility in August 2009 and building costs of $6.4 million related to the Atlanta Facility in March 2010, and recorded corresponding financial obligations. We allocated the lease payments between the building and the land of each facility based upon estimated relative fair values. The portion of the lease payments associated with the building reduces the facility lease obligation, while the portion associated with the land is treated as payment of an operating lease obligation.
	The Orange County Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 1.46%. The estimated lease term is based on an initial 10.5-year term and a 5-year renewal. The Orange County Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation related to this facility, based upon the estimated 15.5-year term, was $5.4 million as of September 30, 2013.
	The Atlanta Facility lease obligation has an extended term of 15.5 years with an effective interest rate of 3.37%. The estimated lease term is based on an initial 10.5-year term and a 5-year renewal. The Atlanta Facility lease may be renewed for up to an additional 20 years beyond the estimated 15.5-year term. The remaining facility lease obligation related to this facility, based upon the estimated 15.5-year term, was $5.5 million as of September 30, 2013.

Convertible_Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2013
Convertible Notes [Abstract]	'
Convertible Notes	'
	10. CONVERTIBLE NOTES
	2016 Notes
	On January 14, 2011, we entered into an underwriting agreement with J.P. Morgan Securities LLC (the “Underwriter”) relating to the offer and sale of $540 million aggregate principal amount of 2016 Notes. Under the terms of the underwriting agreement, we granted the Underwriter an option, exercisable within 30 days of the date of the agreement, to purchase up to an additional $80 million aggregate principal amount of 2016 Notes to cover overallotments. We issued $540 million in aggregate principal amount of 2016 Notes upon the closing of the offering on January 20, 2011. Net proceeds, after payment of underwriting fees and expenses, were $528.8 million. On January 31, 2011, the Underwriter exercised the overallotment option in full, and we closed on the sale of the additional $80 million in principal amount of 2016 Notes on February 3, 2011. Net proceeds from the exercise of the overallotment option, after payment of underwriting fees and expenses, were $78.3 million.
	On January 20, 2011, we entered into the First Supplemental Indenture (the “Supplemental Indenture”) with The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), to our existing Base Indenture (the “Base Indenture” and, together with the Supplemental Indenture, the “2016 Indenture”), dated as of March 16, 2007. The 2016 Indenture sets forth the rights and provisions governing the 2016 Notes. Interest at 2.875% per annum is payable on the 2016 Notes semi-annually in arrears on January 15 and July 15 of each year. Record dates for payment of interest on the 2016 Notes are each January 1 and July 1. The maturity date of the 2016 Notes is January 15, 2016, unless earlier converted.
	The 2016 Notes are convertible at the option of the holder, and we may choose to satisfy conversions, if any, in cash, shares of our common stock, or a combination of cash and shares of our common stock, based on a conversion rate initially equal to 19.5160 shares of common stock per $1,000 principal amount of 2016 Notes, which is equivalent to an initial conversion price of $51.24 per share. The conversion rate will be increased under certain circumstances described in the 2016 Indenture; however, the number of shares of common stock issued upon conversion of a 2016 Note will not exceed 27.3224 per $1,000 principal amount of 2016 Notes, subject to adjustment in accordance with the 2016 Indenture. Should a holder exercise the conversion option during the next twelve-month period, it is our intention to satisfy the conversion with shares of common stock. Consequently, the 2016 Notes are classified as a long-term liability as of September 30, 2013 and December 31, 2012.
	The conversion rate will be adjusted upon the occurrence of certain events, including stock dividends or share splits, the issuance of rights, options or warrants, spin-offs or other distribution of property, cash dividends or distributions, or tender offers or exchange offers. We will not make an adjustment to the conversion rate for any transaction described above (other than share splits or share combinations) if each holder of 2016 Notes has the right to participate in such transaction at the same time and upon the same terms as holders of common stock, and solely as a result of holding 2016 Notes, without having to convert 2016 Notes, as if a number of shares of common stock were held equal to the applicable conversion rate multiplied by the principal amount of 2016 Notes held.
	If a “fundamental change,” as defined in the 2016 Indenture, occurs, holders of 2016 Notes may require us to repurchase all or a portion of their 2016 Notes for cash at a repurchase price equal to 100% of the principal amount of 2016 Notes to be repurchased, plus any accrued and unpaid interest and other amounts due thereon. However, if a fundamental change occurs and a holder elects to convert 2016 Notes, we will, under certain circumstances, increase the applicable conversion rate for 2016 Notes surrendered for conversion by a number of additional shares of common stock, based on the date on which the fundamental change occurs or becomes effective and the price paid per share of common stock in the fundamental change as specified in the 2016 Indenture. At our option, we will satisfy our conversion obligation with cash, shares of common stock or a combination of cash and shares, unless the consideration for common stock in any fundamental change is comprised entirely of cash, in which case the conversion obligation will be paid in cash. The number of additional shares of common stock was determined such that the fair value of the additional shares would be expected to approximate the fair value of the convertible option at the date of the fundamental change.
	In addition, we may from time to time increase the conversion rate, to the extent permitted by law, by any amount for any period of time if the period is at least 20 business days and we provide 15 business days prior written notice of such increase. We may increase the conversion rate if the Board of Directors determines that such increase would avoid or diminish United States federal income tax to holders of common stock in connection with a dividend or distribution. The 2016 Indenture contains customary covenants.
	The 2016 Notes are accounted for in accordance with FASB Accounting Standards Codification 470-20 (“ASC 470-20”), Debt with Conversion and Other Options, under which issuers of certain convertible debt instruments that may be settled entirely or partially in cash upon conversion are required to separately account for the liability (debt) and equity (conversion option) components of the instrument. The liability component of the 2016 Notes, as of the issuance date, was calculated by estimating the fair value of a similar liability issued at an 8.1% effective interest rate, which was determined by considering the rate of return investors would require in the Company’s debt structure. The amount of the equity component was calculated by deducting the fair value of the liability component from the principal amount of the 2016 Notes and resulted in a corresponding debt discount. The debt discount is being amortized as interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any.
	The application of ASC 470-20 resulted in the initial recognition of $132.9 million as the debt discount recorded in additional paid-in capital for the 2016 Notes. The net carrying amount of the liability component, which is recorded as a long-term liability in the consolidated balance sheets, and the remaining unamortized debt discount were as follows:
		September 30,		December 31,
		2013		2012
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		-67,674		-87,256
	Carrying amount of the liability component	$	552,326	$	532,744
	We incurred debt issuance costs of $12.9 million related to the 2016 Notes. In accordance with ASC 470-20, we allocated $10.1 million of debt issuance costs to the liability component of the 2016 Notes, and are amortizing these costs to interest expense through the earlier of the maturity date of the 2016 Notes or the date of conversions, if any. The remaining debt issuance costs of $2.8 million was allocated to the equity component of the 2016 Notes and recorded as an offset to additional paid-in capital.
	Amortization of the debt discount and debt issuance costs resulted in non-cash interest expense of $7.2 million and $21.1 million for the three and nine months ended September 30, 2013, respectively, and $6.6 million and $19.5 million for the three and nine months ended September 30, 2012, respectively. In addition, interest expense recognized on the 2.875%  stated coupon rate was $4.5 million for each of the three months ended September 30, 2013 and 2012, and $13.4 million for each of the nine months ended September 30, 2013 and 2012.
	We have identified other embedded derivatives associated with the 2016 Notes and are accounting for these embedded derivatives accordingly. These embedded derivatives meet certain criteria and are therefore not required to be accounted for separately from the 2016 Notes.
	2014 Notes
	In 2007, an aggregate of $85.3 million of 2014 Notes was sold in a private placement to qualified institutional buyers. Proceeds from the offering, after deducting placement fees and expenses of $3.0 million, were $82.3 million. The 2014 Notes were issued at face principal amount and pay interest of 4.75% per annum on a semi-annual basis in arrears on June 15 and December 15 of each year. Record dates for payment of interest on the 2014 Notes are each June 1 and December 1. The maturity date of the 2014 Notes is June 15, 2014, unless earlier converted.
	In certain circumstances, additional amounts may become due as additional interest. We can elect that the sole remedy for an event of default for our failure to comply with the “reporting obligations” provisions of the indenture under which the 2014 Notes were issued (the “2014 Indenture”) for the first 180 days after the occurrence of such event of default would be for the holders of the 2014 Notes to receive additional interest on the 2014 Notes at an annual rate equal to 1% of the outstanding principal amount of the 2014 Notes.
	The 2014 Notes are convertible into our common stock at the option of the holder, initially at a conversion price of $10.28 per share, equal to a conversion rate of 97.2644 shares per $1,000 principal amount of 2014 Notes, subject to adjustment. There may be an increase in the conversion rate of the 2014 Notes under certain circumstances described in the 2014 Indenture; however, the number of shares of common stock issued will not exceed 114.2857 per $1,000 principal amount of 2014 Notes.
	If a “fundamental change,” as defined in the 2014 Indenture, occurs, holders of 2014 Notes may require us to repurchase all or a portion of their 2014 Notes for cash at a repurchase price equal to 100% of the principal amount of 2014 Notes to be repurchased, plus any accrued and unpaid interest and other amounts due thereon. However, a holder that converts 2014 Notes in connection with a fundamental change may, in some circumstances, be entitled to an increased conversion rate (i.e., a lower per share conversion price) as a make whole premium. The increased conversion rates were determined such that the fair value of the additional shares would be expected to approximate the fair value of the convertible option at the date of the fundamental change.
	In addition, the conversion rate will be adjusted upon the occurrence of certain events, including stock dividends or share splits, the issuance of rights or warrants, other distribution of property, cash dividends or distributions, or tender offers or exchange offers. We will not make an adjustment to the conversion rate for any transaction described above (other than share splits or share combinations) if each holder of 2014 Notes has the right to participate in such transaction at the same time and upon the same terms as holders of common stock, and solely as a result of holding 2014 Notes, without having to convert 2014 Notes and as if a number of shares of common stock were held equal to the applicable conversion rate multiplied by the principal amount of 2014 Notes held.
	In addition, we may from time to time increase the conversion rate, to the extent permitted by law, by any amount for any period of time if the period is at least 20 business days and we provide 15 business days prior written notice of such increase. We may increase the conversion rate if the Board of Directors determines that such increase would avoid or diminish United States federal income tax to holders of common stock in connection with a dividend or distribution. The 2014 Indenture contains customary covenants.
	As of September 30, 2013 and December 31, 2012, the aggregate principal amount of the 2014 Notes outstanding was $27.7 million. As the 2014 Notes have a contractual maturity date of June 15, 2014, the balance is classified as a current liability as of September 30, 2013. We recorded interest expense, including the amortization of debt issuance costs, related to the 2014 Notes of $0.4 million during each of the three months ended September 30, 2013 and 2012, and $1.1 million during each of the nine months ended September 30, 2013 and 2012.
	We have identified embedded derivatives associated with the 2014 Notes and are accounting for these embedded derivatives accordingly. These embedded derivatives meet certain criteria and are therefore not required to be accounted for separately from the 2014 Notes.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation [Abstract]	'
Stock-Based Compensation	'
	11. STOCK-BASED COMPENSATION
	Our equity-based employee incentive plans are described more fully in Note 12 in the 2012 Form 10-K, and in the Definitive Proxy Statement for the 2013 Annual Meeting of Stockholders. Our stock-based awards include stock options, restricted stock awards, and cash-settled stock appreciation rights.
	We recorded stock-based compensation expense in the consolidated statements of operations as follows:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
		(In thousands)
	Cost of revenue	$	468	$	-108	$	655	$	4,841
	Research and development		1,085		1,488		3,347		5,337
	Selling, general and administrative		4,899		6,814		8,095		45,396
	Restructuring		—		1,690		9		1,690
		$	6,452	$	9,884	$	12,106	$	57,264
	We have granted restricted stock awards and stock options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may cause the awards or options to accelerate and vest. For the three and nine months ended September 30, 2013, we recognized $0.2 million and $0.7 million, respectively, of compensation expense related to awards and options with performance conditions. For the three months ended September 30, 2012, compensation expense recognized related to awards and options with performance conditions was not material. For the nine months ended September 30, 2012, we recognized $0.3 million of compensation expense related to awards and options with performance conditions.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model. For the nine months ended September 30, 2013, we recognized $0.2 million of compensation expense related to cash-settled stock appreciation rights. Amounts recognized for the three months ended September 30, 2013 were not material. As of September 30, 2013, we had approximately $0.7 million of unrecognized compensation expense related to our unvested cash-settled stock appreciation rights. We expect to recognize this compensation expense over a period of 1.6 years.
	As further described in Note 2 – Summary of Significant Accounting Policies, in the first and second quarters of 2013, we adjusted our estimated forfeiture rates based on historical forfeiture data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense by $5.8 million for the nine months ended September 30, 2013.
	The fair value of stock options was estimated at the date of grant using the BSM model with the following weighted average assumptions:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Weighted average estimated fair value per share	$	2.04	$	3.21	$	2.97	$	5.59
	Weighted Average Assumptions
	Dividend yield (a)		0.0%		0.0%		0.0%		0.0%
	Expected volatility (b)		86%		86%		85%		69%
	Risk-free interest rate (c)		1.54%		0.80%		0.98%		0.82%
	Expected term (d)		5.0 years		5.5 years		5.0 years		4.8 years
	(a) We have not paid dividends in the past and do not plan to pay dividends in the near future.
	(b) The expected stock price volatility is based on the weighted average historical volatility of our stock.
	(c) The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
	The following summarizes stock option activity:
			Number of Shares		Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
	Outstanding at January 1, 2013		3,757,704	$	18.71
	Granted		359,722		6.20
	Exercised		-8,256		4.98
	Forfeited and expired		-882,848		24.92
	Outstanding at September 30, 2013		3,226,322		15.83		7.4	$	720
	Options exercisable at September 30, 2013		1,577,811		20.92		6.1	$	—
	As of September 30, 2013 we had $3.0 million of unrecognized compensation expense related to our unvested stock options. We expect to recognize this compensation expense over a weighted-average period of 1.2 years.
	The following summarizes restricted stock award activity:
			Number of Shares		Weighted-Average Grant Date Fair Value
	Outstanding at January 1, 2013		4,217,355	$	13.87
	Granted		3,559,986		5.72
	Vested		-1,977,324		12.87
	Forfeited and expired		-909,866		13.07
	Outstanding at September 30, 2013		4,890,151		7.45
	As of September 30, 2013, we had $14.4 million in total unrecognized compensation expense related to restricted stock awards, which will be recognized over a weighted-average period of 1.2 years.

Restructuring_And_Contract_Ter

Restructuring And Contract Termination	9 Months Ended
	Sep. 30, 2013
Restructuring And Contract Termination [Abstract]	'
Restructuring And Contract Termination	'
	12. RESTRUCTURING AND CONTRACT TERMINATION
	Restructuring – 2013
	On November 12, 2013, we announced a restructuring plan further discussed in Note 14 – Subsequent Events. We recorded a restructuring charge of $1.2 million in the third quarter of 2013 related to fees associated with planning and developing the restructuring plan.
	Restructuring – 2012
	On July 30 2012, we announced that our Board of Directors had approved a strategic restructuring plan that included re-configuring our manufacturing model with the closure of the New Jersey Facility, restructuring administrative functions and strengthening commercial functions, which lowered our overall cost structure. The restructuring initiatives included a reduction in workforce of approximately 600 full-time and contractor positions. The employees affected by the workforce reduction were notified the week of September 17, 2012.
	On December 20, 2012, we announced the sale of the New Jersey Facility to Novartis for $43.0 million. As part of the agreement with Novartis, approximately 100 employees at the facility who were previously included in the workforce reduction were offered jobs with Novartis.
	As a result of this workforce reduction, we recorded a charge of $20.1 million during 2012 related to severance, other termination benefits, outplacement services and non-cash stock-based compensation due to the accelerated vesting of options and restricted stock awards of certain employees with employment agreements. In addition, we recorded restructuring charges of $7.8 million during 2012 related to fees associated with planning and developing the restructuring plan, relocation benefits offered to employees, expenses associated with the closure of the New Jersey Facility and other related expenses.
	During the nine months ended September 30, 2013, we recorded charges of $1.4 million related to severance, other termination benefits and outplacement services. These charges were offset by adjustments to reduce the restructuring liability by $1.3 million for the nine months ended September 30, 2013 related to outplacement services and COBRA benefits not used by employees and severance and other termination benefits that will not be paid. We do not expect to incur additional restructuring charges for employee severance benefits related to the 2012 workforce reduction. The implementation of these restructuring initiatives has been substantially completed.
	In addition, we recorded restructuring charges of $1.7 million during the nine months ended September 30, 2013 related to relocation benefits offered to employees, expenses associated with the closure of the New Jersey Facility, contract termination expenses and other related expenses.
	Contract Termination – 2011
	On September 1, 2011 we provided written notice to GlaxoSmithKline LLC (“GSK”) of termination of a Development and Supply Agreement (the “GSK Agreement”) effective on October 31, 2011. We entered into the GSK Agreement for the commercial production and supply of the antigen used in the manufacture of PROVENGE. We exercised our right to terminate the GSK Agreement when, after unforeseen delays, GSK failed to complete the process implementation phase on or before September 1, 2011 pursuant to the terms of the GSK Agreement.
	As further described in Note 13 – Commitments and Contingencies, GSK filed a lawsuit against the Company in November 2011, purporting claims for monies due and owing and breach of the Company’s obligations under the GSK Agreement. On April 9, 2013, GSK amended its complaint to add a claim for breach of North Carolina’s unfair and deceptive trade practices act. Although the ultimate financial impact of the lawsuit is not yet determinable, we expect to pay approximately $4.0 million in fees in connection with the termination of the GSK Agreement. This amount is included in “Restructuring and contract termination liabilities” on the consolidated balance sheets as of September 30, 2013 and December 31, 2012.
	The following is a rollforward of restructuring liabilities:
		Restructuring and Contract Termination Liabilities as of December 31, 2012		Charges, Net of Adjustments		Payments		Other Non-Cash Settlement		Restructuring and Contract Termination Liabilities as of September 30, 2013
	2013 Restructuring:	(In thousands)
	Other associated costs	$	—	$	1,184	$	-847	$	—	$	337
	2012 Restructuring:
	Severance and other termination benefits		10,083		105		-9,751		-9		428
	Other associated costs		108		1,666		-1,696		—		78
	Asset impairment		—		-109		—		109		—
	2011 Restructuring:
	Contract termination costs		4,023		-2		-21		—		4,000
	Total	$	14,214	$	2,844	$	-12,315	$	100	$	4,843
	Total restructuring charges of $2.8 million are included in “Restructuring, contract termination and asset impairment” on our consolidated statement of operations for the nine months ended September 30, 2013. We expect that the remaining liabilities associated with severance and other termination benefits related to the 2012 restructuring will be fully paid by the end of 2013.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments And Contingencies [Abstract]	'
Commitments And Contingencies	'
	13. COMMITMENTS AND CONTINGENCIES
	We have a supply agreement with Fujifilm covering the commercial production of the recombinant antigen used in the manufacture of PROVENGE. The second amendment to the supply agreement extended the term of the agreement through December 31, 2018. Unless terminated, the agreement will renew automatically thereafter for additional 5-year terms. The agreement may be terminated upon written notice by us or Fujifilm at least 24 months before the end of a renewal term or by either party in the event of an uncured material breach or default by the other party.
	We had a commitment as of September 30, 2013 with Fujifilm to purchase antigen of $29.3 million. We expect that payments on this commitment will continue through 2014.
	As described in Note 5 – Inventory, in the third quarter of 2013, we recorded a charge of $6.3 million related to antigen inventory which was determined to fall out of quality specification and was not usable for commercial production. This charge is included in “Cost of product revenue” on our consolidated statement of operations for the three and nine months ended September 30, 2013. We have filed an insurance claim to seek recovery of the $6.3 million loss; however, at this time we are uncertain if this loss will be reimbursed by our insurance carriers.
	We have also identified an additional $38.0 million of antigen inventory at risk of being out of quality specification. We have initiated an investigation to determine the usability of this remaining antigen inventory. If we determine that this inventory is not usable for commercial production, we will seek reimbursement for the loss from our insurance carriers; however, at this time we are uncertain if the loss, if any, will be reimbursed by our insurance carriers.
	We have operating lease obligations related to two leases in Seattle, Washington which cover our principal corporate offices and research facility, a corporate office lease in Bridgewater, New Jersey, and the land portions of our two manufacturing facility leases in Orange County, California and Atlanta, Georgia.
	In February 2011, we entered into a lease for office space of 179,656 square feet in Seattle, Washington with an initial lease term of five and a half years and one renewal term of two and a half years. In July 2012, we amended the lease to reduce the premises to 158,081 square feet. The related rent reduction took effect in November 2012. In April 2013, we amended the lease to further reduce the premises to 112,915 square feet. Rent payments related to the space relinquished in April 2013 will cease effective October 2013 and August 2014. In addition, in April 2013, we subleased to a third party an additional 22,583 square feet at these premises, commencing in May 2013 through the remaining lease term.
	In February 2011, we entered into a sublease for laboratory and office space of 97,365 square feet in Seattle, Washington. The lease term is for eight years.  In July 2012, we entered into a lease for office space of 39,937 square feet in Bridgewater, New Jersey.  The initial lease term is for ten years, with one renewal term of five years.
	In August 2009, we entered into an agreement to lease the Orange County Facility, comprising approximately 184,000 square feet, for use as a manufacturing facility following build-out. The initial lease term is ten and a half years, expiring in December 2019, with five renewal terms of five years each. In July 2009, we entered into an agreement to lease the Atlanta Facility, comprising approximately 156,000 square feet, for use as a manufacturing facility following build-out. The lease commenced when we took possession of the building upon substantial completion of construction of the building shell in March 2010. The initial lease term is ten and a half years, with five renewal terms of five years each.
	We account for the Orange County Facility and the Atlanta Facility as assets with related facility lease obligations due to our significant investment in the build-out of the facilities. The lease payments are allocated to the building and land based on their estimated relative fair values. The portion of the lease related to land is treated as an operating lease. The portion of the lease related to the building is treated as a facility lease obligation as further discussed in Note 9 – Financing Obligations.
	As previously reported, the Company and three current and former officers were named defendants in a consolidated putative securities class action proceeding filed in August 2011 with the United States District Court for the Western District of Washington (the “District Court”) under the caption In re Dendreon Corporation Class Action Litigation, Master Docket No. C 11-1291 JLR. The lawsuit was settled on terms set out in a Stipulation of Settlement (the “Stipulation”) filed with the District Court on April 24, 2013.  Following final settlement approval by the District Court on August 2, 2013, the settlement has become final and effective as provided in the Stipulation; and the litigation has been dismissed against all defendants with prejudice.
	On May 16, 2013, a group of individual shareholders who elected to opt out of the class action settlement commenced their own action alleging securities fraud.  That action, captioned Christoph Bolling, et al. v. Dendreon Corporation, et al., Case No. 2:13-CV- 872 JLR, names the same defendant parties and alleges generally that the Company made various false or misleading statements between April 29, 2010 and August 3, 2011 concerning the Company, its finances, business operations and prospects with a focus on the market launch of PROVENGE and related forecasts concerning physician adoption, and revenue from sales of PROVENGE. In addition to claims under the federal securities laws, the plaintiff group also purports to assert certain claims under Washington state law.  Based on information provided informally by plaintiffs’ counsel, the plaintiff group, which totals approximately 30 persons, purports to have purchased approximately 250,000 shares of Dendreon common stock during the relevant period, an amount that equates to under 0.5% of the estimated shares that comprised the plaintiff class in the class action.  The Bolling plaintiffs filed an amended complaint July 16, 2013. On August 9, 2013, the defendants filed a motion to dismiss plaintiffs’ amended complaint.  Briefing has concluded; we cannot predict whether the Court will entertain oral argument or when the Court may issue a ruling on the motion. Until the motion to dismiss is resolved, discovery in the Bolling action is stayed. We cannot predict the outcome of the motion.  If the litigation proceeds, however, the Company intends to defend the claims vigorously.
	Related to the securities lawsuits, the Company also is the subject of stockholder derivative complaints first filed in August 2011 generally arising out of the facts and circumstances that are alleged to underlie the securities action. Derivative suits filed in the District Court were consolidated into a proceeding captioned In re Dendreon Corp. Derivative Litigation, Master Docket No. C 11-1345 JLR; others were filed in the Superior Court of Washington for King County and were consolidated into a proceeding captioned In re Dendreon Corporation Shareholder Derivative Litigation, Lead Case No. 11-2-29626-1 SEA. On June 22, 2012, another derivative action was filed in the Court of Chancery of the State of Delaware, captioned Herbert Silverberg, derivatively on behalf of Dendreon Corporation v. Mitchell H. Gold, et al., Case No. 7646-VCP. The complaints filed in Washington all name as defendants the three individuals who are defendants in the securities action together with the other members of the Company’s Board of Directors. While the complaints filed in Washington assert various legal theories of liability, the lawsuits generally allege that the defendants breached fiduciary duties owed to the Company in connection with the launch of PROVENGE and by purportedly subjecting the Company to potential liability for securities fraud. The complaints also include claims against certain defendants for supposed misappropriation of Company information and insider trading; the Silverberg complaint, which names one additional former officer of the Company as a defendant, asserts only this claim. The Company filed a motion to dismiss the Silverberg action on standing grounds; the motion is fully briefed and was argued on September 10, 2013. Proceedings in the Silverberg action are otherwise stayed. We cannot predict the outcome of the motion to dismiss or the timing of a decision. While the Company has certain indemnification obligations, including obligations to advance legal expense to the named defendants for defense of these lawsuits, the purported derivative lawsuits do not seek relief against the Company. Additionally, the Securities and Exchange Commission (“SEC”) is conducting a formal investigation, which the Company believes relates to some of the same issues raised in the securities and derivative actions. The Company is cooperating fully with the SEC investigation. The ultimate financial impact of these various proceedings, if any, is not yet determinable and therefore, no provision for loss, if any, has been recorded in the financial statements. With respect to all of the above-described proceedings, the Company has insurance that it believes affords coverage for much of the anticipated costs, subject to the policies’ terms and conditions.
	The Company received notice in November 2011 of a lawsuit filed in the Durham County Superior Court of North Carolina against the Company by GSK. The lawsuit purports claims for monies due and owing and breach of the Company’s obligations under the GSK Agreement terminated as of October 31, 2011. On April 9, 2013, GSK amended its complaint to add a claim for breach of North Carolina’s unfair and deceptive trade practices act. The Company does not believe the lawsuit has merit, filed a Counterclaim and Answer on January 6, 2012, and intends to defend its position vigorously. The Company expects to pay approximately $4.0 million in fees in connection with the termination of the GSK Agreement. The ultimate financial impact of the lawsuit is not yet determinable. Therefore, no additional provision for loss has been recorded in the financial statements.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	14. SUBSEQUENT EVENTS
	Announcement of Restructuring Plan
	On November 12, 2013, we announced that we are restructuring the Company and implementing additional cost reduction measures. The plan includes a reduction in our workforce of approximately 150 full-time employees who will be notified the week of November 12, 2013.
	As a result of this restructuring plan, we expect to record an initial restructuring charge of approximately $7.5 million related to severance and other related termination benefits in the fourth quarter of 2013 and first quarter of 2014.
	We will implement the plan immediately and expect that the benefits will begin to be realized as early as the first quarter of 2014. We expect the restructuring initiatives will take up to 6 months to implement.

Business_Principles_Of_Consoli1

Business, Principles Of Consolidation, And Basis Of Presentation (Policy)	9 Months Ended
	Sep. 30, 2013
Business, Principles Of Consolidation, And Basis Of Presentation [Abstract]	'
Business	'
	Business
	Dendreon Corporation (referred to as “Dendreon,” the “Company,” “we,” “us,” or “our”), a Delaware corporation, is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients. Our product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers.
	PROVENGE® (sipuleucel-T), is our first commercialized product approved by the United States Food and Drug Administration (“FDA”), and is a first-in-class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Commercial sale of PROVENGE began in May 2010. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second leading cause of cancer deaths in men in the United States. We own worldwide rights for PROVENGE.
Principles Of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Dendreon and its direct and indirect wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Basis Of Presentation	'
	Basis of Presentation
	The accompanying unaudited financial statements reflect, in the opinion of management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations and cash flows for each period presented in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from the accompanying statements. These interim financial statements should be read in conjunction with the audited financial statements and related notes thereto, included in our Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Form 10-K”). The accompanying financial information as of December 31, 2012 has been derived from the Company’s audited 2012 consolidated financial statements included in the 2012 Form 10-K. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of future results that may be expected for the year ending December 31, 2013, or any other future period.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue primarily from the sale of PROVENGE. Revenue from the sale of PROVENGE is recorded net of product returns and estimated price discounts, including rebates and chargebacks offered pursuant to mandatory federal and state government programs and to members of Group Purchasing Organizations (“GPOs”) with which we have contracts. Revenue from sales of PROVENGE is recognized upon confirmed product delivery to and issuance of a product release form to the physician. Product returns are limited to those instances in which the physician receives the product but does not infuse the product prior to expiry, either due to timing or the failure of the product to meet specifications and pass site inspection. Due to the limited usable life of PROVENGE of approximately 18 hours from the completion of the manufacturing process to patient infusion, actual return information is known and credited against sales in the month incurred.
	PROVENGE sales are direct to physician; however, we have entered into distribution agreements with several credit-worthy third-party wholesalers (the “Wholesalers”) whereby we manufacture and ship the product direct to the physician and transfer the sale of PROVENGE to the Wholesalers. Under the distribution agreements, the Wholesalers assume all bad debt risk from the physician or institution; therefore no allowance for bad debt is recorded. Under the terms of the distribution agreements, our return policy allows for the return of product that has expired or has a defect prior to delivery, product that is damaged during delivery and product that cannot be infused because it does not otherwise meet specified requirements.
	Our product is subject to certain required pricing discounts via rebates and/or chargebacks pursuant to mandatory federal and state government programs and, accordingly, revenue recognition requires estimates of rebates and chargebacks.
	We have agreements with the Centers for Medicare and Medicaid Services (“CMS”) providing for a rebate on sales to eligible Medicaid patients. For sales of our product to eligible Medicaid patients, the physician purchases our product at full price, and then receives reimbursement from the applicable state. The state, in turn, invoices us for the amount of the Medicaid rebate. Estimated rebates payable under Medicaid are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based on historical claim information. Medicaid rebates were not material for each period presented.
	We also have agreements with the Public Health Service (“PHS”), providing for a chargeback on sales to PHS-eligible providers, and Federal Supply Schedule (“FSS”) customers, including the Department of Veteran Affairs and the Department of Defense, providing for a chargeback on sales to eligible patients. Chargebacks occur when a contracted physician purchases our product at fixed contract prices that are lower than the price we charge the Wholesalers. Each Wholesaler, in turn, charges us back for the difference between the price initially paid by the Wholesaler and the contract price paid to the Wholesaler by the physician. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable.
	The following is a roll forward of our chargebacks reserve associated with the PHS and FSS programs:
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		10,426		12,837
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,128		—
	Payments/credits		-8,399		-13,394
	Balance at September 30	$	3,006	$	6,558
	We have entered into agreements with certain GPOs that contract for the purchase of PROVENGE on behalf of their members and provide contract administration services. Beginning in July of 2012, eligible members of the GPOs purchase PROVENGE at contracted prices through a chargeback. These chargebacks are estimated and recorded in the period that the related revenue is recognized, resulting in a reduction in gross product revenue and trade accounts receivable. We recorded chargebacks related to the GPOs of $2.4 million and $5.2 million for the three and nine months ended September 30, 2013, respectively, and $0.1 million for each of the three and nine months ended September 30, 2012.
	Eligible members of the GPOs may also be entitled to receive a rebate on eligible purchases of PROVENGE at the end of each quarter. Estimated rebates and administrative fees payable to GPOs are recognized in the same period that the related revenue is recognized, resulting in a reduction in gross product revenue, and are classified as other accrued liabilities until paid. Our estimate of rebates payable is based upon information we gather related to sales of our product to eligible GPO members. The following is a roll forward of our accrued GPO rebates and administrative fees balance:
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		4,682		5,719
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-5,054		-4,734
	Balance at September 30	$	1,578	$	1,927
Inventory	'
	Inventory
	Inventories are determined at the lower of cost or market value with cost determined under the specific identification method. We began capitalizing raw material inventory in mid-April 2009, in anticipation of the potential approval for marketing of PROVENGE in the first half of 2010. At this time, our expectation of future benefits became sufficiently high to justify capitalization of these costs, as regulatory approval was considered probable and the related costs were expected to be recoverable through the commercialization of the product. Costs incurred prior to mid-April 2009 were recorded as research and development expense in the statements of operations, which resulted in zero-cost inventory.
	For the nine months ended September 30, 2012, we used $4.7 million of zero-cost inventory; no zero-cost inventory remained on hand as of June 30, 2012. As a result, cost of product revenue reflects a lower average per unit cost of raw material in the first half of 2012.
Restructuring And Contract Termination Expenses	'
	Restructuring and Contract Termination Expenses
	We record a liability for costs associated with an exit or disposal activity at fair value in the period in which the liability is incurred. Employee termination benefits are accrued when the obligation is probable and estimable. Employee termination benefits are expensed at the date the employee is notified unless the employee must provide future service in excess of 60 days, in which case such benefits are expensed ratably over the future service period. For contract termination costs, we record a liability upon the later of the contract termination date or the date we cease using the rights conveyed by the contract. Refer to Note 12 – Restructuring and Contract Termination for details of restructuring expenses recorded in the third quarter of 2013 and Note 14 – Subsequent Events for additional actions that will be implemented in the fourth quarter of 2013.
Impairment Of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	We periodically evaluate the carrying value of long-lived assets to be held and used when events and circumstances indicate that the carrying amount of an asset may not be recovered. When evaluating long-lived assets for impairment, we compare the carrying value of the asset to the asset's estimated undiscounted future cash flows. Impairment is recorded if the estimated future cash flows are less than the carrying value of the asset. The impairment loss recognized, if any, is the excess of the asset’s carrying value over the fair value of the long-lived asset. The determination of fair value of the assets evaluated for impairment requires the use of judgmental assumptions surrounding the amount and timing of future cash flows and the highest and best use of the assets.
	The long-lived assets at our manufacturing facilities in Atlanta, Georgia and in Orange County, California represent our most significant long-lived assets and have an average remaining estimated useful life of approximately 7.5 years.  Our determination of the cash flows used to support the recoverability of these assets requires us to estimate future revenue growth and costs of operations, requiring significant management judgments. The estimates we used to forecast the future operating results are consistent with the plans and estimates that we use to manage our business. Significant assumptions utilized in this analysis as of September 30, 2013 included maintaining our current revenue levels and successfully implementing the cost reduction measures as further discussed in Note 14 – Subsequent Events. The recoverability test is particularly sensitive to our estimates of future revenue and operating expenses. For example, in our recoverability analysis as of September 30, 2013, a decrease in our revenue assumptions for future periods of less than 2%, without a corresponding decrease in operating expenses, would have indicated that the undiscounted cash flows were insufficient to recover the carrying value of our facility assets. In this analysis, the undiscounted cash flows exceeded the current net book value of our facility assets by 10%. Although we believe that our current underlying assumptions supporting this assessment are reasonable, if actual product revenues do not meet the levels we have forecasted or if we do not achieve the reductions in operating expense we have forecasted, we may be required to update the assumptions in our impairment analysis. Such updates to this analysis may impact the recoverability of these assets, which may result in a material charge to our statement of operations.
Accounting For Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	Stock-based compensation cost is estimated at the grant date based on the award’s fair value and is recognized on the accelerated method as expense over the requisite service period. The fair value of stock options is calculated using the Black-Scholes-Merton (“BSM”) option pricing model. The BSM model requires various judgmental assumptions regarding volatility and expected option life. If any of the assumptions used in the BSM model change significantly, stock-based compensation expense for new awards may differ materially from that recorded for existing awards. We determine the fair value of awards under our Employee Stock Purchase Plan using the BSM model.
	Restricted stock awards generally vest and are expensed over two- to four-year periods. We have granted restricted stock awards and options with certain performance conditions to certain executive officers and key employees. At each reporting date, we evaluate whether achievement of the performance conditions is probable. Compensation expense is recorded over the appropriate service period based upon our assessment of accomplishing each performance provision or the occurrence of other events which may have caused the awards or options to accelerate and vest.
	In the second quarter of 2013, we granted cash-settled stock appreciation rights with a two-year vest period to certain employees. These awards are classified as liabilities and are measured at fair value at each reporting date, with fair value being determined using the BSM model.
	Stock-based compensation expense also requires the estimate of forfeiture rates. In the first and second quarters of 2013, we adjusted our estimated forfeiture rates based on historical forfeiture data, resulting in cumulative catch-up adjustments to decrease stock-based compensation expense and net loss by $5.8 million for the nine months ended September 30, 2013. These adjustments decreased basic and diluted net loss per share by $0.04 for the nine months ended September 30, 2013.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding. For the calculation of diluted net loss per share, we have excluded all outstanding stock options, unvested restricted stock and shares issuable upon potential conversion of the 2.875% Convertible Senior Notes due 2016 (the “2016 Notes”) and the 4.75% Convertible Senior Subordinated Notes due 2014 (the “2014 Notes”) from the calculation because all such securities are anti-dilutive, and accordingly, our diluted net loss per shares is the same as basic net loss per share. For the three and nine months ended September 30, 2013 and 2012, the computation of diluted net loss per share excluded 22.9 million shares and 23.1 million shares, respectively.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) includes charges and credits to stockholders’ equity that are not the result of transactions with stockholders. Our comprehensive loss consisted of net loss plus changes in unrealized gain or loss on investments for the three and nine months ended September 30, 2013 and 2012.
Loss Contingencies	'
	Loss Contingencies
	A loss contingency is recorded if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. We evaluate, among other factors, the probability of an unfavorable outcome and our ability to make a reasonable estimate of the amount of the ultimate loss. Loss contingencies that we determine to be reasonably possible, but not probable, are disclosed but not recorded. Changes in these estimates could materially affect our financial position and results of operations.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (the “FASB”) issued an Accounting Standards Update which requires companies to provide information about the amounts reclassified from accumulated other comprehensive income to net income by component. In addition, companies are required to present, either on the face of the statements of operations or in the notes to the financial statements, significant amounts reclassified from accumulated other comprehensive income by statement of operations line item. There were no reclassifications from accumulated other comprehensive income to net income for the three and nine months ended September 30, 2013.
	In June 2013, the FASB ratified Emerging Issues Task Force (“EITF”) Issue 13-C, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists,” which concludes that an unrecognized tax benefit should be presented as a reduction of a deferred tax asset when settlement in this manner is available under the tax law. We will adopt this amendment as of January 2014, and do not believe it will have any impact on our financial position, results of operations or cash flows.
	For a more detailed listing of our significant accounting policies, see Note 2 of the consolidated financial statements included in the 2012 Form 10-K.

Summary_Of_Significant_Account2

Summary Of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies [Abstract]	'
Schedule Of Chargebacks Reserve	'
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	3,107	$	7,065
	Current provision related to sales made in current period		10,426		12,837
	Current provision related to sales made in prior periods		—		50
	Adjustments		-2,128		—
	Payments/credits		-8,399		-13,394
	Balance at September 30	$	3,006	$	6,558
Schedule Of Accrued Rebates and Administrative Fees	'
		Nine Months Ended September 30,
		2013		2012
		(in thousands)
	Beginning balance, January 1	$	1,950	$	885
	Current provision related to sales made in current period		4,682		5,719
	Current provision related to sales made in prior periods		—		57
	Payments/credits		-5,054		-4,734
	Balance at September 30	$	1,578	$	1,927

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
Schedule Of Available For Sale Securities	'
		Cost or Amortized Cost		Fair Market Value
		(In thousands)
	September 30, 2013
	Due in one year or less	$	78,893	$	78,947
	Due after one year through two years		66,687		66,708
		$	145,580	$	145,655
	December 31, 2012
	Due in one year or less	$	165,295	$	165,396
	Due after one year through two years		75,999		76,045
		$	241,294	$	241,441
Short-Term And Long-Term Securities Available-For-Sale	'
		Cost or Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Market Value
		(In thousands)
	September 30, 2013
	Demand deposit	$	5,404	$	—	$	—	$	5,404
	Corporate debt securities		94,535		46		-24		94,557
	Government-sponsored enterprises		13,147		20		—		13,167
	U.S. Treasury notes		32,494		33		—		32,527
		$	145,580	$	99	$	-24	$	145,655
	December 31, 2012
	Demand deposit	$	5,641	$	—	$	—	$	5,641
	Corporate debt securities		104,652		91		-17		104,726
	Government-sponsored enterprises		33,438		18		—		33,456
	U.S. Treasury notes		97,563		57		-2		97,618
		$	241,294	$	166	$	-19	$	241,441

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis	'
	3 an
	Description	Balance		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)
	Assets:	(In thousands)
	September 30, 2013
	Money market	$	83,289	$	83,289	$	—
	Corporate debt securities		94,557		—		94,557
	Government-sponsored enterprises		13,167		—		13,167
	U.S. Treasury notes		32,527		—		32,527
	Total financial assets		223,540	$	83,289	$	140,251
	Add: Cash		9,809
	Total cash, cash equivalents and investments	$	233,349
	December 31, 2012
	Money market	$	184,167	$	184,167	$	—
	Corporate debt securities		104,726		—		104,726
	Government-sponsored enterprises		33,456		—		33,456
	U.S. Treasury notes		97,618		—		97,618
	Total financial assets		419,967	$	184,167	$	235,800
	Add: Cash		9,882
	Total cash, cash equivalents and investments	$	429,849

Property_And_Equipment_Tables

Property And Equipment (Tables)	9 Months Ended
	Sep. 30, 2013
Property And Equipment [Abstract]	'
Schedule Of Components Of Property And Equipment	'
		September 30,		December 31,
		2013		2012
		(In thousands)
	Furniture and office equipment	$	2,792	$	2,111
	Laboratory and manufacturing equipment		29,903		29,590
	Computer equipment and software		69,158		66,117
	Leasehold improvements		117,242		115,735
	Buildings		17,872		17,872
	Construction in progress		2,112		2,313
		$	239,079	$	233,738
	Less accumulated depreciation		-106,949		-83,134
		$	132,130	$	150,604

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Schedule Of Components Of Accrued Liabilities	'
		September 30,		December 31,
		2013		2012
		(In thousands)
	Deferred rent	$	7,193	$	7,875
	Inventory receipts		15,672		6,636
	Accrued consulting and other services		7,249		12,016
	Accrued clinical trials expense		2,909		2,299
	Accrued interest		4,097		8,234
	Accrued service fees and rebates		2,467		3,533
	Other accrued liabilities		6,902		4,228
		$	46,489	$	44,821

Convertible_Notes_Tables

Convertible Notes (Tables)	9 Months Ended
	Sep. 30, 2013
Convertible Notes [Abstract]	'
Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount	'
		September 30,		December 31,
		2013		2012
		(In thousands)
	Aggregate principal amount of 2016 Notes	$	620,000	$	620,000
	Unamortized discount of the liability component		-67,674		-87,256
	Carrying amount of the liability component	$	552,326	$	532,744

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation [Abstract]	'
Schedule Of Components Of Stock Compensation Expense	'
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
		(In thousands)
	Cost of revenue	$	468	$	-108	$	655	$	4,841
	Research and development		1,085		1,488		3,347		5,337
	Selling, general and administrative		4,899		6,814		8,095		45,396
	Restructuring		—		1,690		9		1,690
		$	6,452	$	9,884	$	12,106	$	57,264
Schedule Of Weighted Average Assumptions For Employee Stock Options	'
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Weighted average estimated fair value per share	$	2.04	$	3.21	$	2.97	$	5.59
	Weighted Average Assumptions
	Dividend yield (a)		0.0%		0.0%		0.0%		0.0%
	Expected volatility (b)		86%		86%		85%		69%
	Risk-free interest rate (c)		1.54%		0.80%		0.98%		0.82%
	Expected term (d)		5.0 years		5.5 years		5.0 years		4.8 years
	(a) We have not paid dividends in the past and do not plan to pay dividends in the near future.
	(b) The expected stock price volatility is based on the weighted average historical volatility of our stock.
	(c) The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
	(d)The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies.
Summary Of Stock Option Activity	'
			Number of Shares		Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
	Outstanding at January 1, 2013		3,757,704	$	18.71
	Granted		359,722		6.20
	Exercised		-8,256		4.98
	Forfeited and expired		-882,848		24.92
	Outstanding at September 30, 2013		3,226,322		15.83		7.4	$	720
	Options exercisable at September 30, 2013		1,577,811		20.92		6.1	$	—
Summary Of Restricted Stock Award	'
			Number of Shares		Weighted-Average Grant Date Fair Value
	Outstanding at January 1, 2013		4,217,355	$	13.87
	Granted		3,559,986		5.72
	Vested		-1,977,324		12.87
	Forfeited and expired		-909,866		13.07
	Outstanding at September 30, 2013		4,890,151		7.45

Restructuring_And_Contract_Ter1

Restructuring And Contract Termination (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring And Contract Termination [Abstract]	'
Rollforward Of Restructuring Liabilities	'
		Restructuring and Contract Termination Liabilities as of December 31, 2012		Charges, Net of Adjustments		Payments		Other Non-Cash Settlement		Restructuring and Contract Termination Liabilities as of September 30, 2013
	2013 Restructuring:	(In thousands)
	Other associated costs	$	—	$	1,184	$	-847	$	—	$	337
	2012 Restructuring:
	Severance and other termination benefits		10,083		105		-9,751		-9		428
	Other associated costs		108		1,666		-1,696		—		78
	Asset impairment		—		-109		—		109		—
	2011 Restructuring:
	Contract termination costs		4,023		-2		-21		—		4,000
	Total	$	14,214	$	2,844	$	-12,315	$	100	$	4,843

Summary_Of_Significant_Account3

Summary Of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Product usable life	'	'	'18 hours	'
Zero cost inventory usage	'	'	'	$4.70
Estimated useful life of long-lived assets	'	'	'7 years 6 months	'
Threshold decrease as a percentage of future period revenues indicating insufficient cash flows to recover carrying value of facility assets	'	'	2.00%	'
Percentage by which undiscounted future cash flows exceeded current net book value of facility assets in analysis	'	'	10.00%	'
Future service period threshold for ratably expensing employee termination benefits	'	'	'60 days	'
Cumulative catch-up adjustment to reduce stock-based compensation expense	'	'	5.8	'
Decrease to net loss per share	'	'	$0.04	'
Shares excluded from net loss per share	'	'	22.9	23.1
Convertible Senior Notes Due 2014 [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Interest rate of debt	4.75%	'	4.75%	'
Debt instrument maturity year	'	'	'2014	'
Convertible Senior Notes Due 2016 [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Interest rate of debt	2.88%	'	2.88%	'
Debt instrument maturity year	'	'	'2016	'
Stock Appreciation Rights [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'2 years	'	'	'
Group Purchasing Organization [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Chargebacks recognized	$2.40	$0.10	$5.20	$0.10
Minimum [Member] | Restricted Stock [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'	'	'2 years	'
Maximum [Member] | Restricted Stock [Member]	'	'	'	'
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'
Vesting period	'	'	'4 years	'

Summary_Of_Significant_Account4

Summary Of Significant Accounting Policies (Schedule Of Chargebacks Reserve) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]	'	'
Beginning balance, January 1	$3,107	$7,065
Current provision related to sales made in current period	10,426	12,837
Current provision related to sales made in prior periods	'	50
Adjustments	-2,128	'
Payments/credits	-8,399	-13,394
Balance at September 30	$3,006	$6,558

Summary_Of_Significant_Account5

Summary Of Significant Accounting Policies (Schedule Of Estimated And Accrued Rebates and Administrative Fees) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Summary Of Significant Accounting Policies [Abstract]	'	'
Beginning balance, January 1	$1,950	$885
Current provision related to sales made in current period	4,682	5,719
Current provision related to sales made in prior periods	'	57
Payments/credits	-5,054	-4,734
Balance at September 30	$1,578	$1,927

Investments_Narrative_Details

Investments (Narrative) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Investments [Abstract]	'	'
Investments securing letters of credit	$5.40	$5.60

Investments_Schedule_Of_Availa

Investments (Schedule Of Available-For-Sale Securities) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Investments [Abstract]	'	'
Due in one year or less, Cost or Amortized Cost	$78,893	$165,295
Due after one year through two years, Cost or Amortized Cost	66,687	75,999
Total debt securities available for sale, Cost or Amortized Cost	145,580	241,294
Due in one year or less, Fair Market Value	78,947	165,396
Due after one year through two years, Fair Market Value	66,708	76,045
Total debt securities available for sale, Fair Market Value	$145,655	$241,441

Investments_Schedule_Of_ShortT

Investments (Schedule Of Short-Term And Long-Term Securities Available-For-Sale) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	$145,580	$241,294
Gross Unrealized Gains	99	166
Gross Unrealized Losses	-24	-19
Total debt securities available for sale, Fair Market Value	145,655	241,441
Demand Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	5,404	5,641
Total debt securities available for sale, Fair Market Value	5,404	5,641
Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	94,535	104,652
Gross Unrealized Gains	46	91
Gross Unrealized Losses	-24	-17
Total debt securities available for sale, Fair Market Value	94,557	104,726
Government-Sponsored Enterprises [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	13,147	33,438
Gross Unrealized Gains	20	18
Total debt securities available for sale, Fair Market Value	13,167	33,456
U.S. Treasury Notes [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost or Amortized Cost	32,494	97,563
Gross Unrealized Gains	33	57
Gross Unrealized Losses	'	-2
Total debt securities available for sale, Fair Market Value	$32,527	$97,618

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Convertible Senior Notes Due 2016 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fair value of convertible notes	$378.60	$471.20
Convertible Senior Notes Due 2014 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Fair value of convertible notes	$26.30	$25.30

Fair_Value_Measurements_Schedu

Fair Value Measurements (Schedule Of Financial Assets Measured At Fair Value On A Recurring Basis) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$223,540	$419,967
Add: Cash	9,809	9,882
Total cash, cash equivalents and investments	233,349	429,849
Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	83,289	184,167
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	140,251	235,800
Money Market [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	83,289	184,167
Money Market [Member] | Quoted Prices In Active Markets For Identical Assets (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	83,289	184,167
Money Market [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	'	'
Corporate Debt Securities [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	94,557	104,726
Corporate Debt Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	94,557	104,726
Government-Sponsored Enterprises [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	13,167	33,456
Government-Sponsored Enterprises [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	13,167	33,456
U.S. Treasury Notes [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	32,527	97,618
U.S. Treasury Notes [Member] | Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Financial Statement Captions [Line Items]	'	'
Financial assets	$32,527	$97,618

Inventory_Details

Inventory (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Inventory [Abstract]	'	'
Raw materials	$96.10	$76.30
Expense related to antigen inventory not useable for commercial production	6.3	'
Antigen at risk for being out of specification	$38	'

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Details) (Prepaid Expenses And Other Current Assets [Member], USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Prepaid Expenses And Other Current Assets [Member]	'	'
Prepaid antigen costs	$0.50	$0.60
Costs associated with agreements to develop second source suppliers for materials and to qualify a contract manufacturer for production	$6.90	$8.50

Property_And_Equipment_Narrati

Property And Equipment (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Property And Equipment [Abstract]	'	'	'	'
Depreciation expense	$8.10	$9.50	$23.80	$31.20

Property_And_Equipment_Schedul

Property And Equipment (Schedule Of Components Of Property And Equipment) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$239,079	$233,738
Less accumulated depreciation	-106,949	-83,134
Property and equipment, net	132,130	150,604
Furniture And Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	2,792	2,111
Laboratory And Manufacturing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	29,903	29,590
Computer Equipment And Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	69,158	66,117
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	117,242	115,735
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	17,872	17,872
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$2,112	$2,313

Accrued_Liabilities_Schedule_O

Accrued Liabilities (Schedule Of Components Of Accrued Liabilities) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]	'	'
Deferred rent	$7,193	$7,875
Inventory receipts	15,672	6,636
Accrued consulting and other services	7,249	12,016
Accrued clinical trials expense	2,909	2,299
Accrued interest	4,097	8,234
Accrued service fees and rebates	2,467	3,533
Other accrued liabilities	6,902	4,228
Accrued liabilities	$46,489	$44,821

Financing_Obligations_Details

Financing Obligations (Details) (USD $)	9 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Aug. 31, 2009	Sep. 30, 2013	Mar. 31, 2010
	Orange County Facility [Member]	Orange County Facility [Member]	Atlanta Facility [Member]	Atlanta Facility [Member]
Capital Leased Assets [Line Items]	'	'	'	'
Amount capitalized related to fair value of building owned	'	$6.70	'	$6.40
Extended term of lease, years	'15 years 6 months	'	'15 years 6 months	'
Effective interest rate of facility leases	1.46%	'	3.37%	'
Initial term of lease, years	'10 years 6 months	'	'10 years 6 months	'
Extension period of lease renewal term	'5 years	'	'5 years	'
Estimated term of facility lease	'15 years 6 months	'	'15 years 6 months	'
Additional renewal term, years	'20 years	'	'20 years	'
Aggregate remaining obligation of facility leases	$5.40	'	$5.50	'

Convertible_Notes_2016_Notes_D

Convertible Notes (2016 Notes) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Feb. 03, 2011	Jan. 20, 2011	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
			Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Convertible Senior Notes Due 2016 [Member]	Maximum [Member]
									Equity Component [Member]	Liability Component [Member]	Convertible Senior Notes Due 2016 [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Face amount of notes issued	$620,000,000	$620,000,000	$80,000,000	$540,000,000	'	'	'	'	'	'	'
Debt instrument maturity year	'	'	'	'	'	'	'2016	'	'	'	'
Proceeds from issuance of convertible senior notes	'	'	78,300,000	528,800,000	'	'	'	'	'	'	'
Convertible senior notes initial conversion price	'	'	'	'	$51.24	'	$51.24	'	'	'	'
Minimum number of days conversion rate increase must last	'	'	'	'	'	'	'20 days	'	'	'	'
Number of days written notice that is required prior to a conversion rate increase	'	'	'	'	'	'	'15 days	'	'	'	'
Convertible senior notes conversion ratio	'	'	'	'	'	'	0.019516	'	'	'	0.0273224
Debt instrument effective interest rate	'	'	'	'	8.10%	'	8.10%	'	'	'	'
Interest rate of debt	'	'	'	'	2.88%	'	2.88%	'	'	'	'
Payments of debt issuance costs	'	'	'	'	'	'	12,900,000	'	2,800,000	10,100,000	'
Carrying amount of the equity component	'	'	'	'	132,900,000	'	132,900,000	'	'	'	'
Convertible senior notes repurchase price	'	'	'	'	'	'	100.00%	'	'	'	'
Non-cash interest expense on debt discount and debt issuance costs	'	'	'	'	7,200,000	6,600,000	21,100,000	19,500,000	'	'	'
Interest on convertible senior notes based on stated coupon rate	'	'	'	'	$4,500,000	$4,500,000	$13,400,000	$13,400,000	'	'	'

Convertible_Notes_2014_Notes_D

Convertible Notes (2014 Notes) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Jul. 31, 2007	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
			Convertible Senior Notes Due 2014 [Member]	Convertible Senior Notes Due 2014 [Member]	Convertible Senior Notes Due 2014 [Member]	Convertible Senior Notes Due 2014 [Member]	Convertible Senior Notes Due 2014 [Member]	Maximum [Member]
								Convertible Senior Notes Due 2014 [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Face amount of notes issued	$620,000,000	$620,000,000	$85,300,000	'	'	'	'	'
Payments of debt issuance costs	'	'	3,000,000	'	'	'	'	'
Proceeds from issuance of convertible senior notes	'	'	82,300,000	'	'	'	'	'
Interest rate of debt	'	'	4.75%	'	'	'	'	'
Debt instrument maturity year	'	'	'	'	'	'2014	'	'
Additional interest rate percentage	'	'	'	'	'	1.00%	'	'
Convertible senior notes initial conversion price	'	'	'	$10.28	'	$10.28	'	'
Convertible senior notes conversion ratio	'	'	'	'	'	0.0972644	'	0.1142857
Convertible senior notes repurchase price	'	'	'	'	'	100.00%	'	'
Minimum number of days conversion rate increase must last	'	'	'	'	'	'20 days	'	'
Number of days written notice that is required prior to a conversion rate increase	'	'	'	'	'	'15 days	'	'
Current portion of convertible debt	27,685,000	'	'	27,700,000	'	27,700,000	'	'
Aggregate convertible notes principal amount outstanding	'	27,685,000	'	'	'	'	'	'
Interest on convertible senior notes based on stated coupon rate	'	'	'	$400,000	$400,000	$1,100,000	$1,100,000	'

Convertible_Notes_Schedule_Of_

Convertible Notes (Schedule Of Carrying Amount Of Liability Component And Remaining Unamortized Discount) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Convertible Notes [Abstract]	'	'
Aggregate principal amount of 2016 Notes	$620,000,000	$620,000,000
Unamortized discount of the liability component	-67,674,000	-87,256,000
Carrying amount of the liability component	$552,326,000	$532,744,000

StockBased_Compensation_Narrat

Stock-Based Compensation (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$6,452,000	$9,884,000	$12,106,000	$57,264,000
Cumulative catch-up adjustment to reduce stock-based compensation expense	'	'	5,800,000	'
Restricted Stock [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized stock compensation expense related to unvested stock options	14,400,000	'	14,400,000	'
Approximate period of recognition of unrecognized stock compensation expense related to unvested stock options, in years	'	'	'1 year 2 months 12 days	'
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized stock compensation expense related to unvested stock options	3,000,000	'	3,000,000	'
Approximate period of recognition of unrecognized stock compensation expense related to unvested stock options, in years	'	'	'1 year 2 months 12 days	'
Performance Shares [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	200,000	'	700,000	300,000
Cash-Settled Stock Appreciation Rights [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized stock compensation expense related to unvested stock options	700,000	'	700,000	'
Approximate period of recognition of unrecognized stock compensation expense related to unvested stock options, in years	'	'	'1 year 7 months 6 days	'
Vesting period	'2 years	'	'	'
Stock-based compensation expense	$200,000	'	$200,000	'

StockBased_Compensation_Schedu

Stock-Based Compensation (Schedule Of Components Of Stock Compensation Expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	$6,452	$9,884	$12,106	$57,264
Cost Of Product Revenue [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	468	-108	655	4,841
Research And Development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	1,085	1,488	3,347	5,337
Selling, General And Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	4,899	6,814	8,095	45,396
Restructuring [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock compensation expense	'	$1,690	$9	$1,690

StockBased_Compensation_Schedu1

Stock-Based Compensation (Schedule Of Weighted Average Assumptions For Employee Stock Options) (Details) (Employee Stock Options [Member], USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012
Employee Stock Options [Member]	'		'		'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'		'		'
Weighted average estimated fair value per share	$2.04		$3.21		$2.97		$5.59
Dividend yield	0.00%	[1]	0.00%	[1]	0.00%	[1]	0.00%	[1]
Expected volatility	86.00%	[2]	86.00%	[2]	85.00%	[2]	69.00%	[2]
Risk-free interest rate	1.54%	[3]	0.80%	[3]	0.98%	[3]	0.82%	[3]
Expected term (in years)	'5 years	[4]	'5 years 6 months	[4]	'5 years	[4]	'4 years 8 months 12 days	[4]
[1]	We have not paid dividends in the past and do not plan to pay dividends in the near future.
[2]	The expected stock price volatility is based on the weighted average historical volatility of our stock.
[3]	The risk-free interest rate is based on the implied yield available on United States Treasury zero-coupon issues with a term equal to the expected life of the award on the date of grant.
[4]	The expected term of options granted represents the estimated period of time until exercise and is based on the historical weighted average term of similar awards, giving consideration to the contractual terms, vesting schedules, expectations of future employee behavior and the terms of certain peer companies

StockBased_Compensation_Summar

Stock-Based Compensation (Summary Of Stock Option Activity) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation [Abstract]	'
Outstanding at January 1, 2013	3,757,704
Granted	359,722
Exercised	-8,256
Forfeited and expired	-882,848
Outstanding at September 30, 2013	3,226,322
Options exercisable at September 30, 2013	1,577,811
Weighted-Average Exercise Price per Share, Outstanding at January 1, 2013	$18.71
Weighted-Average Exercise Price per Share, Granted	$6.20
Weighted-Average Exercise Price per Share, Exercised	$4.98
Weighted-Average Exercise Price per Share, Forfeited and expired	$24.92
Weighted-Average Exercise Price per Share, Outstanding at September 30, 2013	$15.83
Weighted-Average Exercise Price per Share, Options exercisable at September 30, 2013	$20.92
Weighted-Average Remaining Contractual Life (in years), Outstanding at September 30, 2013	'7 years 4 months 24 days
Weighted-Average Remaining Contractual Life (in years), Options exercisable at September 30, 2013	'6 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding at September 30, 2013	$720

StockBased_Compensation_Summar1

Stock-Based Compensation (Summary Of Restricted Stock Award) (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
Stock-Based Compensation [Abstract]	'
Outstanding at January 1, 2013	4,217,355
Granted	3,559,986
Vested	-1,977,324
Forfeited and expired	-909,866
Outstanding at September 30, 2013	4,890,151
Weighted-Average Grant Date Fair Value, Outstanding at January 1, 2013	$13.87
Weighted-Average Grant Date Fair Value, Granted	$5.72
Weighted-Average Grant Date Fair Value, Vested	$12.87
Weighted-Average Grant Date Fair Value, Forfeited and expired	$13.07
Weighted-Average Grant Date Fair Value, Outstanding at September 30, 2013	$7.45

Restructuring_And_Contract_Ter2

Restructuring And Contract Termination (Narrative) (Details) (USD $)	0 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	1 Months Ended	9 Months Ended		12 Months Ended
	Nov. 12, 2013	Jul. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Dec. 31, 2012
	employee	employee						Novartis [Member]	Agreement With GSK [Member]	Other Associated Costs [Member]	Other Associated Costs [Member]
								employee
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Restructuring charges and contract termination	'	'	$1,188,000	$80,994,000	$2,844,000	$81,969,000	'	'	'	'	'
Reduction in workforce	150	600	'	'	'	'	'	100	'	'	'
Proceeds from sale of facility	'	'	'	'	'	'	'	43,000,000	'	'	'
Charge for severance and other related termination benefits	'	'	'	'	1,400,000	'	20,100,000	'	'	'	'
Adjustment to reduce restructuring liability	'	'	'	'	1,300,000	'	'	'	'	'	'
Restructuring, contract termination and other related expenses	'	'	'	'	'	'	'	'	'	1,700,000	7,800,000
Cancellation fee under development and supply agreement	'	'	'	'	$4,000,000	'	'	'	$4,000,000	'	'

Restructuring_And_Contract_Ter3

Restructuring And Contract Termination (Restructuring Charges And Contract Termination Liabilities) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and Contract Termination Liabilities as of December 31, 2012	'	'	$14,214	'
Charges	1,188	80,994	2,844	81,969
Payments	'	'	-12,315	'
Other Non-Cash Settlement	'	'	100	'
Restructuring and Contract Termination Liabilities as of September 30, 2013	4,843	'	4,843	'
2013 Restructuring [Member] | Other Associated Costs [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Charges	'	'	1,184	'
Payments	'	'	-847	'
Restructuring and Contract Termination Liabilities as of September 30, 2013	337	'	337	'
2012 Restructuring [Member] | Severance And Other Termination Benefits [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and Contract Termination Liabilities as of December 31, 2012	'	'	10,083	'
Charges	'	'	105	'
Payments	'	'	-9,751	'
Other Non-Cash Settlement	'	'	-9	'
Restructuring and Contract Termination Liabilities as of September 30, 2013	428	'	428	'
2012 Restructuring [Member] | Other Associated Costs [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and Contract Termination Liabilities as of December 31, 2012	'	'	108	'
Charges	'	'	1,666	'
Payments	'	'	-1,696	'
Restructuring and Contract Termination Liabilities as of September 30, 2013	78	'	78	'
2012 Restructuring [Member] | Asset Impairment [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Charges	'	'	-109	'
Other Non-Cash Settlement	'	'	109	'
2011 Restructuring [Member] | Contract Termination Costs [Member]	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'
Restructuring and Contract Termination Liabilities as of December 31, 2012	'	'	4,023	'
Charges	'	'	-2	'
Payments	'	'	-21	'
Restructuring and Contract Termination Liabilities as of September 30, 2013	$4,000	'	$4,000	'

Commitments_And_Contingencies_

Commitments And Contingencies (Details) (USD $)	3 Months Ended	9 Months Ended			1 Months Ended		9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jul. 31, 2012	Feb. 28, 2011	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	defendant	item	FujiFilm [Member]	Bridgewater Space [Member]	Seattle Lease [Member]	Seattle Lease [Member]	Seattle Lease [Member]	Seattle Sublease [Member]	Orange County Facility [Member]	Atlanta Facility [Member]	2013 Agreements [Member]
		plaintiff		sqft	sqft	sqft	sqft	sqft	sqft	sqft	FujiFilm [Member]
		defendant		item		item	item		item	item
Commitments And Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Renewal term of supply agreement	'	'	'5 years	'	'	'	'	'	'	'	'
Termination notice period of supply agreement	'	'	'24 months	'	'	'	'	'	'	'	'
Purchase commitment	'	'	'	'	'	'	'	'	'	'	$29.30
Expense related to antigen inventory not useable for commercial production	6.3	'	'	'	'	'	'	'	'	'	'
Antigen at risk for being out of specification	38	38	'	'	'	'	'	'	'	'	'
Number of operating leases	'	'	'	'	'	'	2	'	'	'	'
Rentable space under lease agreement, in square feet	'	'	'	39,937	158,081	179,656	112,915	97,365	184,000	156,000	'
Additional space subleased, in square feet	'	'	'	'	'	'	22,583	'	'	'	'
Term of lease, years	'	'	'	'10 years	'	'5 years 6 months	'	'8 years	'10 years 6 months	'10 years 6 months	'
Number of renewal terms	'	'	'	1	'	1	'	'	5	5	'
Renewal term, years	'	'	'	'5 years	'	'2 years 6 months	'	'	'5 years	'5 years	'
Expected cancellation fees under the Development and Supply Agreement	'	$4	'	'	'	'	'	'	'	'	'
Number of current and former officers who are named defendants	'	3	'	'	'	'	'	'	'	'	'
Number of persons in plaintiff group	'	30	'	'	'	'	'	'	'	'	'
Common stock shares purchased by plaintiff group	'	250	'	'	'	'	'	'	'	'	'
Percentage of estimated shares in plaintiff class	'	0.50%	'	'	'	'	'	'	'	'	'
Number of defendants	3	3	'	'	'	'	'	'	'	'	'
Number of additional defendants	1	1	'	'	'	'	'	'	'	'	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	0 Months Ended			3 Months Ended	0 Months Ended
In Millions, unless otherwise specified	Nov. 12, 2013	Jul. 30, 2012	Nov. 12, 2013	Dec. 31, 2013	Nov. 12, 2013
	employee	employee	Announcement Of Restructuring Plan [Member]	Announcement Of Restructuring Plan [Member]	Scenario, Forecast [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Date of subsequent event	'	'	12-Nov-13	'	'
Reduction in workforce	150	600	'	'	'
Expected initial restructuring charge	'	'	'	'	$7.50
Expected implementation period of restructuring plan	'	'	'	'6 months	'